A Phase I Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Cancer Biliary Tract Cancer Hepatocellular Carcinoma (HCC)
For the latest version of this information please go to www.forpatients.roche.com